Tech Commercialisation Radar Finds Only 32 of 332 Market-Ready Research Results Are Licensable Technologies and None of October’s 11 Licensing Deals Named a University
A reading of 2,884 research and 2,280 corporate records finds that the licensable pipeline sits at TRL 5–6, 177 validated results a median 3.5 years from market with 57 percent of the 209-result pool naming no industrial partner, while 8 of 11 company-to-company licences carried High momentum.

InnoDexis has published its latest Innovation Intelligence Report covering technology commercialisation and what to license next, analyzing 2,884 research records from 41 countries and 1,018 institutions against 2,280 corporate records from 2,157 organisations during the complete 1–31 October 2026 window. The report reveals that ready is not for sale: only 32 of 332 market-ready research results, 9.6 percent, are technologies a company can license, and every one of October’s 11 technology licences was between companies, 8 of them rated High momentum.
Key Findings
Market-ready research is mostly not for sale. Of 332 research results at TRL 7–9, 32 describe a technology with a commercial licensee, while 71 are changes to clinical practice, 65 are evidence for policy makers and public agencies and 14 are open tools or datasets.
The licensable pipeline sits at TRL 5–6. There, 177 of 604 results, 29.3 percent, are licensable technologies, five and a half times the market-ready count, with a median 3.5 years to market by researchers’ own estimates, and 315 more licensable technologies at TRL 3–4 form the option pool.
The pool is largely unclaimed. Of 209 licensable results at TRL 5 or above, 120, 57.4 percent, name no industrial partner and only 26 name a spin-out or startup vehicle, and health supplies 72, energy 31 and AI and software 21.
Licences are company-to-company and carry momentum. All 11 October technology licences, including Astellas–Audax, Novartis–Abogen, AstraZeneca–insitro and CSL’s US$355 million upfront to Alentis, were between companies, and 8 carried High momentum, 73 percent against 14.6 percent across the corporate stream.
Supply and demand sit in different markets. Pharma and biotech draw 3 company announcements per licensable result and medtech and diagnostics 2, against 11 in mobility and 8 in software, semiconductors and materials, and AI platforms show 561 company announcements against 18 licensable results.
Strategic Insight and Trend Analysis
The defining structural finding is that commercialisation is a packaging business. Research supplies licensable technology and the market buys licences, but the two never met directly in October: every licence went from one company to another, and the academic results that reached market did so inside spin-outs that had done the packaging, with 4 of the 6 health licences struck with dedicated biotechnology developers. Public funders back 48 percent of the licensable pool and corporate funders 9 percent.
The readiness scale measures how finished a result is, not whether anyone can buy it. The market-ready band is dominated by clinical guidance and policy evidence, so the licensable share falls from 29 percent at the validated stage to 10 percent at market-ready, and the validated records still name the gap a licensee must close: durability in 81 of 209, real-world validation in 49 and scale-up in 43.
System design shapes licensability. South Korea, Japan and China turn 50, 40 and 33 percent of validated research into licensable technology against 17, 15 and 0 percent in the United States, United Kingdom and Canada, and Germany is the volume exception with 50 licensable results, 21 from Fraunhofer institutes. Classifications rest on text fields spot-checked at about 83 percent precision, and a month of 11 licences is a small base.
Global and Industry Implications
For corporates and R&D teams, re-point scouting from high readiness to licensable, TRL 5–6 and unpartnered, and buy from the laboratory rather than the startup, since 105 of the 177 validated results have no industrial partner. In demand-heavy markets, lock up scarce results such as the Fraunhofer IPA aluminium anode, the KIER perovskite step and Gothenburg’s vehicle-cloud security analysis.
For investors and capital allocators, the packaging step is the investable gap, since only 26 of 209 licensable results name a company vehicle, so fund formation around validated, unpartnered results at TRL 5–6 with a named buyer announcing in the same technique. Named opportunities include NoMIS Power, GlitterinTech and Artikode Intelligence, and announced values should be treated as ceilings, with US$14.6 billion verified against US$102 billion announced.
For policymakers and national innovation bodies, university technology-transfer offices that measure success by direct licences are measuring a route the market is not using, and applied institutes such as Fraunhofer, with 21 licensable results across 17 institutes, are the working intermediary. Regulation is the largest inherited cost, with 116 of the 209 records stating an approval need, so clearance precedents for device classes lower the cost of health licences.
InnoDexis Statement
“Ready is not for sale — the licences the market signs come from companies that have packaged the science, and whoever performs that packaging step for the unpartnered pool captures the value,” noted InnoDexis in its latest intelligence report.
Conclusion
Because the licensable and transfer-route classifications rest on text fields at about 83 percent precision, university licences are often unannounced and one month of 11 licences is a small base, the findings are cross-sectional. The signals to watch are whether a licence announcement names a university co-inventor, whether a validated result in a technique names an industrial partner for the first time, and whether a licensor names a manufacturing partner for a materials or energy result. The complete Tech Commercialisation Radar: What to License Next Report October 2026 is available to InnoDexis subscribers and enterprise clients.
About InnoDexis
InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.
Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.
InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.